Ask AI
ProCE Banner Activity

Expanding Role of MRAs in Heart Failure: Nonsteroidal Finerenone Improves Patient Outcomes and Quality of Life

Clinical Thought

Learn how finerenone compares with steroidal MRAs in treating patients with heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction as well as how to translate the current evidence into your practice.

Released: July 09, 2025

Expiration: July 08, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Bayer HealthCare Pharmaceuticals, Inc.

Bayer HealthCare Pharmaceuticals Inc.

Faculty Disclosure

Primary Author

Ty J. Gluckman, MD, MHA: consultant/advisor/speaker: OptumRx.